The ongoing conflict in West Asia poses a significant threat to India’s pharmaceutical exports, particularly to the Gulf Cooperation Council (GCC) and West Asia and North Africa (WANA) regions. As outlined by the Pharmaceuticals Export Promotion Council of India, the uncertainty surrounding cargo movement is the primary concern. This situation has the potential to cause a financial setback ranging from ₹2,500 crore to ₹5,000 crore for the Indian pharma sector.
Export Vulnerability
The GCC countries represent a vital segment of India’s export market, accounting for approximately 5.58% of total exports. The increase in exports to WANA nations from $1,320.44 million in 2020-21 to $1,749.68 million in 2024-25 highlights the growing importance of these regions for Indian pharmaceutical companies. However, the current geopolitical turmoil threatens to disrupt this growth trajectory.
Freight Charges and Delivery Delays
Namit Joshi, the chairman of Pharmexcil, emphasized the financial strain on pharmaceutical companies due to the doubling of freight charges. Import and export surcharges ranging from $4,000 to $8,000 per shipment exacerbate the situation. Key shipping routes, including the Red Sea and the Strait of Hormuz, face the risk of delays and re-routing, which can severely hinder delivery schedules. This is particularly alarming for temperature-sensitive products that require strict adherence to shipping timelines.
Escalating Costs Across the Supply Chain
The conflict has not only impacted shipping logistics but has also led to escalating costs throughout the supply chain. Fluctuations in crude oil prices and increased logistics costs for active pharmaceutical ingredients (APIs) and finished formulations are expected to disrupt inventory cycles. These challenges necessitate a reevaluation of operational strategies by pharmaceutical companies, as they strive to maintain product availability in international markets.
Strategic Mitigation Efforts
In light of these challenges, Pharmexcil is actively monitoring the situation and engaging with logistics and trade stakeholders. The council is advocating for enhanced collaboration with government authorities to explore potential relief measures. Suggestions include subsidies and logistical support for exporters, diversification of shipping routes, and the exploration of alternative logistics options. These measures aim to stabilize supply chains and ensure the continued availability of products in critical markets.
Market Dependency on Indian Pharmaceuticals
Countries like the UAE, Saudi Arabia, Oman, Kuwait, and Yemen are heavily reliant on India for affordable medicines and generic formulations. Data from Pharmexcil indicate a robust growth trajectory in emerging markets such as Jordan, Kuwait, and Libya. Product categories such as vaccines, surgical products, and AYUSH formulations are gaining traction, further emphasizing the importance of maintaining a stable export environment.
Conclusion
The pharmaceutical sector’s vulnerability to geopolitical conflicts underscores the interconnectedness of global trade. As India’s pharma industry navigates these turbulent waters, proactive measures and strategic collaborations will be crucial for sustaining growth and ensuring access to essential medicines in key markets. The resilience of the sector will depend on its ability to adapt and innovate in response to these challenges.
- Key Takeaways:
- The ongoing conflict in West Asia threatens India’s pharmaceutical exports, with potential losses of ₹2,500 to ₹5,000 crore.
- Freight charges and delivery delays are significantly impacting the pharma supply chain.
- Strategic mitigation efforts are underway to stabilize exports and maintain market presence.
- Emerging markets are increasingly reliant on Indian pharmaceuticals, highlighting the need for continued access to affordable medicines.
Read more → www.thehindu.com